Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sionna Therapeutics

Request full access

Dedicated to delivering therapies that could be transformational for people living with cystic fibrosis

Waltham, United StatesFounded 2019Biotech & Life Sciences

About Sionna Therapeutics

Sionna Therapeutics is a biotechnology startup that is focused on revolutionizing the treatment of cystic fibrosis (CF). The company is developing innovative small molecule therapies that target the most common genetic mutation in CF patients, known as ΔF508. Their ultimate goal is to normalize CFTR function, which is a protein that helps control the balance of salt and water in the body. When this protein is not functioning properly, it leads to the symptoms of CF.

Sionna operates in the healthcare market, specifically within the realm of genetic diseases. Their clients are primarily patients suffering from cystic fibrosis, a life-threatening genetic disorder that severely damages the lungs and digestive system.

The business model of Sionna Therapeutics is centered around the research, development, and eventual commercialization of their novel therapies. They generate revenue through the successful development and sale of these therapies to healthcare providers who then administer them to CF patients.

The company prides itself on its collaborative approach to drug discovery, with a team that is dedicated to making a positive impact on patients' lives. They are currently in the DC / IND-Enabling stage, which means they are conducting necessary studies and preparing to submit an Investigational New Drug (IND) application to the FDA. This is a crucial step in the process of getting a new drug approved for use in patients.

Source: Dealroom company data

At a glance

Status
Operational
Employees
74
Open positions
2
Dealroom signal
92.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Disease, Rumoured $1B, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPOOther financing Feb 2025 $191M $191M Undisclosed ↗
SERIES COther financing Mar 2024 $182M $728M Atlas Venture · OrbiMed · Viking Global Investors · Perceptive Advisors ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMargin
2026 — —
2025 — —
2024 — —
2023 — —
2022 — —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Sionna Therapeutics website traffic

Latest recorded traffic for Sionna Therapeutics is 7.4K monthly website visits, up 12.1% over the last three months. Sionna Therapeutics's team grew 17.5% over the past year.

Latest monthly visits7.4K 3-month web change+12.1% 1-year team growth+17.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Rectify PharmaceuticalsBreakthrough ABC transporter platform enabling rapid discovery of small molecule therapies for liver, biliary, eye, CNS, and cardiometabolic diseases Cambridge, United States Operational 22 $100M $400M
Stargazer PharmaceuticalsAn ophthalmic biotech company focused on the development of a novel treatment option for a genetic orphan retinal disease with significant unmet medical needs Boston, United States Operational
Regenacy PharmaceuticalsDeveloping ricolinostat to treat diabetic, chemotherapy-induced and inherited peripheral neuropathies Waltham, United States Operational
Thousand Oaks BiopharmaceuticalsA developer of biopharmaceutical technologies intended to produce protein and vaccine compounds Shantou, China Operational
AzurRx BioPharmaAzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies Boca Raton, United States Operational
GlycomineDeveloping orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist San Carlos, United States Operational
MiNA TherapeuticsA platform that enables the development of new medicines that restore normal function to patients’ cells London, United Kingdom Operational
TauRx PharmaceuticalsDeveloping tau aggregation inhibitors for neurodegenerative diseases Aberdeen, United Kingdom Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sionna Therapeutics in the Waltham ecosystem

Live from Dealroom

The Sionna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

Series B and later3 investors entered at this stage

Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sionna Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sionna Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.